arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

REGENERON PHARMACEUTICALS, INC.

REGN
$771.96 ▲ +3.30 (+0.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
72 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
84
Health
Excellent
Bullish
auto_awesome

Analytical Summary

REGENERON PHARMACEUTICALS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $79.4B
Dividend Yield 0.12%
Revenue Growth 16.7%
Op. Margin 30.1%
ROIC 3.3%
FCF / Share $7.91
Trailing P/E 61.2x
Price / Book 2.5x
FCF Yield 1.0%
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Aug 6, 2026.

72-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.29B
↑ +16.7%
Net Income Profit after all expenses
$727.20M
↓ -10.1%
Operating Margin Operating profit as % of sales
30.1%
↑ +69.1% 82th
FCF / Share Free cash flow per share
$7.91
↓ -23.8%
Long-Term Debt Long-term obligations
$1.99B
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
90
Returns
79
Financial Health
90
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$0.94 Latest / share
+0.0% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 19 years · 72 quarters